You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

There’s a lot to remember when taking a GLP-1 medication. Here are 5 ways to use the Lose It! app to help optimize your ...

Decades of studies and statistics have shown that women are consistently held back in the workplace because of their gender.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

FAT jabs like Ozempic are set to get the seal of approval from the World Health Organisation (WHO). This would back the use ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...